This video is intended for U.S. HCPs only.
At Daiichi Sankyo we aim to create essential medicine for longer, better lives. The core and catalyst behind our oncology development plan is our DXd ADC Technology. ADCs, or antibody drug conjugates, are therapies that combine 3 components—an antibody connected to a payload via a linker.
Explore the origins behind our proprietary DXd ADC Technology and learn how this innovative approach provides targeted #cancer therapy through our “Making of DXd ADC” video series.
Learn more about our proprietary DXd ADC Technology: https://bit.ly/3qKHi5w
Source Daiichi Sankyo US YouTube
